While managing trade issues and searching for the proper purchases, Sun Pharmaceutical moves its specialty pipeline and seeks a commercial partner for its MMII drug.

Sun Pharmaceutical is working to find a commercial partner for its promising MMII product which is used for pain from osteoarthritis. After announcing the company’s Q4-FY25 and total full-year financial results, Chairman and Managing Director Dilip Shanghvi revealed the company’s next moves during an analyst call. With Phase II trials finished, MMII now looks forward to further commercial progress.

As part of the company’s strategy evaluation, Sun Pharma is looking at GLOO34, a medicine designed for type 2 diabetes that advanced through Phase I trials and is set for Phase II trials by the second half of FY26. Shanghvi pointed out that the company is making specialty pharmaceuticals a key part of its future plans.

Uncertainty about U.S. tariffs and the MFN pricing policy is waiting to be resolved and this may influence the company’s profitability as it has to pay more in the U.S. compared to Europe. Sun Pharma will spend around $100 million next year to respond to possible changes in government policies.

According to Shanghvi, Sun Pharma can consider valuable deals in acquisitions, adding that being large is not necessarily a barrier as long as the added value is there.

Leqselvi and unloxcyt are part of Sun Pharma’s much-improved specialty pipeline which helps the company keep its promise to grow in the long run.